TCR2 Therapeutics (NASDAQ: TCRR)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-04 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.760 | ||||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of TCR2 Therapeutics (NASDAQ: TCRR) through any online brokerage.
Other companies in TCR2 Therapeutics’s space includes: Adverum Biotechnologies (NASDAQ:ADVM), Ambrx Biopharma (NYSE:AMAM), Immuneering (NASDAQ:IMRX), Fusion Pharmaceuticals (NASDAQ:FUSN) and Gelesis Holdings (NYSE:GLS).
The latest price target for TCR2 Therapeutics (NASDAQ: TCRR) was reported by HC Wainwright & Co. on Thursday, May 19, 2022. The analyst firm set a price target for 14.00 expecting TCRR to rise to within 12 months (a possible 385.27% upside). 10 analyst firms have reported ratings in the last year.
The stock price for TCR2 Therapeutics (NASDAQ: TCRR) is $2.885 last updated Today at June 27, 2022, 6:24 PM UTC.
There are no upcoming dividends for TCR2 Therapeutics.
TCR2 Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for TCR2 Therapeutics.
TCR2 Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.